| Literature DB >> 28713486 |
Giosuè Annibalini1, Francesco Lucertini1, Deborah Agostini1, Luciana Vallorani1, Annamaria Gioacchini1, Elena Barbieri1, Michele Guescini1, Lucia Casadei1, Annunziata Passalia1, Marta Del Sal1, Giovanni Piccoli1, Mauro Andreani2, Ario Federici1, Vilberto Stocchi1.
Abstract
Type 2 diabetes (T2D) is an age-related chronic disease associated with metabolic dysregulation, chronic inflammation, and activation of peripheral blood mononuclear cells (PBMC). The aim of this study was to assess the effects of a concurrent exercise training program on inflammatory status and metabolic parameters of T2D patients. Sixteen male patients (age range 55-70) were randomly assigned to an intervention group (n = 8), which underwent a concurrent aerobic and resistance training program (3 times a week; 16 weeks), or to a control group, which followed physicians' usual diabetes care advices. Training intervention significantly improved patients' body composition, blood pressure, total cholesterol, and overall fitness level. After training, plasma levels of adipokines leptin (-33.9%) and RBP4 (-21.3%), and proinflammatory markers IL-6 (-25.3%), TNF-α (-19.8%) and MCP-1 (-15.3%) decreased, whereas anabolic hormone IGF-1 level increased (+16.4%). All improvements were significantly greater than those of control patients. Plasma proteomic profile of exercised patients showed a reduction of immunoglobulin K light chain and fibrinogen as well. Training also induced a modulation of IL-6, IGF-1, and IGFBP-3 mRNAs in the PBMCs. These findings confirm that concurrent aerobic and resistance training improves T2D-related metabolic abnormalities and has the potential to reduce the deleterious health effects of diabetes-related inflammation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28713486 PMCID: PMC5497609 DOI: 10.1155/2017/3937842
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Patients anthropometrics, body composition, fitness assessment scores, and clinical parameters before and after the intervention.
| Variable | Control group (CON) | Exercise group (EXE) | EXE versus CON | ||||
|---|---|---|---|---|---|---|---|
| Baseline | 16 weeks | % change | Baseline | 16 weeks | % change |
| |
| Age (yr) | 60 ± 6.8 | / | / | 57 ± 9.1 | / | / | / |
| Duration of diabetes (yr) | 7.8 ± 5.2 | / | / | 10.1 ± 7.3 | / | / | / |
| Body weight (kg) | 85.6 ± 10.2 | 86.6 ± 9.9 | 0.5 (−1.2, 2.1) | 85.6 ± 8.2 | 83.5 ± 9.8 | −2.6 (−4.2, −1.1) |
|
| BMI (kg/m2) | 29.0 ± 3.8 | 29.1 ± 3.6 | 0.4 (−1.4, 2.2) | 28.3 ± 1.5 | 27.7 ± 2.1 | −2.5 (−4.2, −0.8) |
|
| Waist circumference (cm) | 102.1 ± 11.1 | 102.4 ± 11.5 | 0.3 (−0.8, 1.4) | 101.2 ± 7.4 | 98.6 ± 6.4 | −2.4 (−3.5, −1.4) |
|
| Hip circumference (cm) | 102.4 ± 6.2 | 102.9 ± 5.9 | 0.5 (−0.7, 1.6) | 103.5 ± 5.0 | 101.4 ± 4.9 | −2.0 (−3.1, −1.0) |
|
| Fat mass (%) | 29.7 ± 2.0 | 30.3 ± 1.2 | 2.0 (−1.3, 5.4) | 29.5 ± 5.9 | 27.5 ± 6.3 | −7.4 (−10.7, −4.0) |
|
| Fat-free mass (%) | 70.3 ± 6.2 | 69.7 ± 5.2 | −0.5 (−2.6, 1.7) | 70.5 ± 5.9 | 72.5 ± 6.3 | 2.8 (2.0, 3.5) |
|
| VO2max (mL/kg/min) | 37.2 ± 7.7 | 37.0 ± 11.5 | −2.3 (−11.0, 6.4) | 33.3 ± 3.8 | 38.9 ± 5.3 | 18.1 (9.9, 26.2) |
|
| 1-RM leg press (kg) | 182.6 ± 31.7 | 188.1 ± 52.4 | 1.6 (−12.6, 15.7) | 168.9 ± 30.5 | 199.7 ± 44.3 | 19.4 (6.1, 32.7) |
|
| m-RM leg press (reps) | 26.4 ± 9.7 | 29.1 ± 6.0 | 27.8 (−19.8, 75.4) | 27.1 ± 6.4 | 47.6 ± 19.0 | 86.9 (42.0, 131.8) |
|
| 1-RM chest press (kg) | 55.1 ± 6.9 | 55.9 ± 6.2 | 0.4 (−0.9, 1.6) | 59.6 ± 13.5 | 68.6 ± 13.6 | 3.7 (2.6, 4.9) |
|
| m-RM chest press (reps) | 31.8 ± 8.5 | 31.6 ± 8.3 | −4.2 (−33.1, 24.8) | 24.5 ± 6.0 | 35.9 ± 14.3 | 45.6 (21.7, 69.5) |
|
| 1-RM lat pull-down (kg) | 74.1 ± 12.1 | 75.3 ± 7.7 | 4.2 (−6.3, 14.6) | 72.6 ± 7.6 | 80.2 ± 13.2 | 9.6 (−0.1, 19.3) |
|
| m-RM lat pull-down (reps) | 46.1 ± 9.9 | 46.3 ± 10.5 | 1.4 (−12.7, 15.4) | 38.3 ± 4.8 | 46.2 ± 4.5 | 20.3 (8.4, 32.3) |
|
| Systolic BP (mmHg) | 130.6 ± 12.4 | 128.1 ± 10.7 | −0.4 (−7.0, 6.2) | 126.6 ± 12.7 | 116.6 ± 12.9 | −8.5 (−14.6, −2.3) |
|
| Diastolic BP (mmHg) | 80.6 ± 3.2 | 82.5 ± 5.3 | 1.8 (−2.3, 5.8) | 81.9 ± 6.3 | 76.6 ± 3.5 | −5.5 (−9.3, −1.7) |
|
| Fasting blood glucose (mg/dL) | 129.4 ± 36.0 | 164.0 ± 59.5 | 58.9 (−0.71, 18.6) | 128.3 ± 27.5 | 123.6 ± 24.3 | −1.5 (−57.8, 54.7) | 0.136 |
| HbA1c (%) | 7.2 ± 1.1 | 6.9 ± 0.8 | −2.6 (−6.4, 1.3) | 7.1 ± 0.8 | 6.7 ± 0.7 | −5.6 (−9.2, −2.0) | 0.236 |
| Total cholesterol (mg/dL) | 183.8 ± 30.3 | 190.4 ± 16.6 | 5.0 (−4.6, 14.9) | 185.1 ± 21.2 | 169.1 ± 34.2 | −8.3 (−17.6, 1.0) |
|
| LDL cholesterol (mg/dL) | 123.3 ± 22.1 | 124.1 ± 12.3 | 7.0 (−6.6, 20.5) | 107.9 ± 16.3 | 105.6 ± 26.7 | −4.7 (−17.4, 8.0) | 0.216 |
| HDL cholesterol (mg/dL) | 41.6 ± 14.2 | 42.7 ± 10.8 | 4.8 (−3.3, 12.9) | 42.1 ± 8.6 | 38.9 ± 4.3 | −4.5 (−13.1, 4.2) | 0.115 |
| Creatininemia (mg/dL) | 0.9 ± 0.1 | 0.9 ± 0.1 | −4.7 (−8.8, −06) | 1.0 ± 0.2 | 0.9 ± 0.2 | −4.2 (−8.1, −0.3) | 0.844 |
BMI: body max index; VO2max: maximal oxygen consumption; 1-RM: 1 repetition maximum; m-RM: multiple RM; BP: blood pressure; HbA1c: glycated hemoglobin; p: level of statistical significance (bold when lower than 0.05). Absolute values are expressed as means ± SD; percentage changes are presented as means and 95% confidence interval.
Concentrations of circulating adipokines, cytokines, chomokines, and hs-CRP before and after the intervention.
| Variable | Control group (CON) | Exercise group (EXE) | EXE versus CON | ||||
|---|---|---|---|---|---|---|---|
| Baseline | 16 weeks | % change | Baseline | 16 weeks | % change |
| |
| Leptin (ng/mL) | 5.7 ± 2.7 | 5.2 ± 2.5 | 16.7 (−7.1, 40.6) | 5.4 ± 1.8 | 3.6 ± 1.5 | −33.9 (−59.3, −8.4) |
|
| Adiponectin ( | 2.9 ± 1.0 | 2.8 ± 1.6 | −3.2 (−20.5, 14.1) | 2.3 ± 0.9 | 2.2 ± 1.0 | −4.8 (−23.4, 13.7) | 0.897 |
| RBP4 ( | 27.7 ± 4.0 | 26.7 ± 5.1 | −5.6 (−12.1, 1.0) | 30.6 ± 9.7 | 22.0 ± 4.4 | −21.3 (−28.3, −14.3) |
|
| IL-6 (pg/mL) | 1.1 ± 0.5 | 1.1 ± 0.5 | 2.0 (−11.5, 15.6) | 1.3 ± 0.5 | 0.8 ± 0.4 | −25.3 (−39.8, −10.8) |
|
| MCP-1 (pg/mL) | 200.4 ± 41.6 | 217.8 ± 51.9 | 11.3 (−1.2, 23.8) | 194.1 ± 42.1 | 166.4 ± 59.0 | −15.3 (−28.7, −1.9) |
|
| TNF- | 2.0 ± 0.2 | 2.1 ± 0.2 | 2.0 (−5.0, 8.9) | 2.1 ± 0.5 | 1.6 ± 0.4 | −19.8 (−25.4, −14.1) |
|
| hs-CRP (mg/L) | 1.0 ± 0.8 | 0.9 ± 0.5 | −12.5 (−81.5, 56.4) | 1.6 ± 1.2 | 1.2 ± 0.5 | 61.3 (5.3, 117.2) | 0.106 |
| IGF-1 (ng/mL) | 58.0 ± 11.3 | 61.3 ± 8.0 | 7.3 (1.0, 13.6) | 57.1 ± 11.4 | 66.4 ± 14.9 | 16.4 (11.3, 21.5) |
|
| IGFBP-3 ( | 1.9 ± 0.1 | 1.9 ± 0.2 | 2.4 (−1.8, 6.5) | 1.8 ± 0.3 | 1.9 ± 0.4 | 3.5 (−1.0, 8.0) | 0.705 |
RBP4: retinol-binding protein 4; IL-6: interleukin-6; MCP-1: monocyte chemotactic protein-1; TNF-α: tumor necrosis factor-alpha; hs-CRP: high sensitivity C-reactive protein; IGF-1: insulin-like growth factor-1; IGFBP-3: insulin-like growth factor binding protein-3; p: level of statistical significance (bold when lower than 0.05). Absolute values are expressed as means ± SD; percentage changes are presented as means and 95% confidence interval.
Figure 12-DE maps of plasma proteins from EXE group before (a) and after (b) the 16-week exercise training program. Differentially expressed spots are indicated by black circles and numbered according to Table 3.
Plasma protein differentially expressed after the intervention.
| Spot | Protein name | NCBI ID |
|---|---|---|
| 1 | Ig kappa chain C region | IGKC_HUMAN |
| 2 | Ig kappa chain V-II region | KV206_HUMAN |
| 3 | Ig kappa chain C region | IGKC_HUMAN |
| 4 | Fibrinogen beta chain | FIBB_HUMAN |
| 5 | Fibrinogen beta chain | FIBB_HUMAN |
| 6 | Retinol-binding protein 4 | RETBP_HUMAN |
| 7 | Apolipoprotein A1 | APOA1_HUMAN |
| 8 | Apolipoprotein E | APOE_HUMAN |
| 9 | Transthyretin | TTR_HUMAN |
Figure 2mRNA expression of IL-6, TNF-α, IGF-1, and IGFBP-3 in peripheral monocytes of control (CON) and exercise (EXE) groups at baseline (white bars) and after the 16-week exercise training program (black bars). Values are means ± SD. ∗Significant between-group differences, as assessed by ANCOVA (baseline values as covariates).